ALRNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	85 369.00
平均出来高	67 785.00
時価総額	84.86M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.460
ATR14	$0.0190 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Von Rickenbach Josef H	Buy	2 725	Stock Option (right to buy)
2024-02-28	Ambros Reinhard J.	Buy	2 725	Stock Option (right to buy)
2024-03-25	Garner Charles	Sell	349 750	Stock Option (right to buy)
2024-03-25	Garner Charles	Sell	25 597	Stock Option (right to buy)
2024-03-05	Windsor James Brian	Buy	2 000	Common Stock

INSIDER POWER
-82.25
Last 95 transactions
Buy: 24 990 503 \| Sell: 1 525 640

ボリューム相関

長: -0.12 (neutral)

短: 0.57 (weak)

Signal:(33.738) Neutral

Aileron Therapeutics Inc 相関

10 最も正の相関
TTOO	0.931
DCRC	0.918
BNIXU	0.918
JRJC	0.912
REVB	0.91
AVIR	0.909
IMPL	0.908
IMV	0.908
JFU	0.899
LSXMA	0.899

10 最も負の相関
CSII	-0.934
ATCX	-0.932
PAE	-0.931
MELI	-0.93
KIN	-0.926
NYMTZ	-0.922
SCR	-0.919
PCYG	-0.918
ZIXI	-0.915
HPK	-0.913

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aileron Therapeutics Inc 相関 - 通貨/商品

-0.29
( neutral )

-0.12
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.09
( neutral )

0.07
( neutral )

Aileron Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-119 000 (0.00 %)
EPS:	$-3.42

FY	2023
収益:	$0
総利益:	$-119 000 (0.00 %)
EPS:	$-3.42

FY	2022
収益:	$0
総利益:	$-169 000 (0.00 %)
EPS:	$-5.95

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-13.31

Financial Reports:

No articles found.

Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.